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 Homeostasis Model Assessment (HOMA) 
and M Value in Daily Profile of Glucose
Abstract
Background: Low Carbohydrate Diet (LCD) and Calorie Restriction (CR) have been on discussion for years. 
Authors have continued diabetic research about LCD, CR, Morbus (M) value and insulin secretion. In this study, 
homeostasis model assessment (HOMA) was investigated. 
Subjects and Methods: Subjects enrolled were 52 patients with type 2 diabetes mellitus (T2DM) (average 62.3 
years). Methods included the measurement of fasting glucose and immunoreactive insulin (IRI), daily profile of 
blood glucose and M value. 
Results:The obtained data were as follows: average HbA1c 8.0%, average glucose of daily profile 222mg/dL. 
Median data were M value 151, HOMA-R 1.07, HOMA-β 11.1. Divided into 4 groups due to M value, the levels of 
HOMA-R and HOMA-β in each group were 0.68, 1.08, 1.64, 1.38 and 16.9, 16.3, 10.2, 5.3, respectively. Significant 
correlation were observed between M value and HOMA-R (p<0.01), and between M value and HOMA-β (p<0.01). 
Discussion and Conclusion: As M value increases, HOMA-R increases and HOMA-β decreases. These findings 
suggested that diabetic patients would have insulin resistance and decreased β cell function correlated to the 
severity of diabetes, and that obtained results would become the basal data in this field, expecting the further 
development in the future research. 
Keywords: Type 2 diabetes mellitus (T2DM), Morbus value (M value), Homeostasis model assessment of insulin 
resistance (HOMA-R), Homeostasis model assessment of β cell function (HOMA-β), Daily profile of blood glucose, 
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Introduction
Diabetes mellitus has been increasing and becoming medical 
and social problems in many countries. There are various 
developments for diagnosis and treatment of diabetes. Recently, 
managements of diabetes have been proposed by International 
Diabetes Federation (IDF), American Diabetes Association 
(ADA) and American College of Physicians (ACP) [1-3]. One of 
the controversies was the point concerning the recommended 
HbA1c in some situations.
The problem of diabetes has been known for its complications. 
They include microangiopathic complication with neuropathy, 
retinopathy and nephropathy, and macroangiopathic 
complication with arteriosclerosis of brain, heart and lower 
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extremities [4]. On the basis of these complications, there are 
crucial pathophysiological problems, including insulin resistance 
and impaired insulin secretion. These diabetic function could 
be studied as useful biomarker as the homeostasis model 
assessment (HOMA) such as HOMA-R and HOMA-β [5].
Regarding nutritional therapy for diabetes, recent focus has 
been the problem of carbohydrate intake. In clinical setting, 
the discussion has continued about the comparison with Low 
Carbohydrate Diet (LCD) and Calorie restriction (CR) [6-8]. LCD 
means the decreased intake of carbohydrate as meals, and 
CR means the decreased intake of fat leading to less calorie 
restriction. 
LCD was started by Atkins and others in North American 
and European countries [9]. After that in Japan, authors and 
colleague researchers initiated LCD project and developed 
through Japan Low Carbohydrate Diet Promotion Association 
[10]. We have continued clinical practice for diabetes with three 
useful LCD methods, which are petit LCD, standard LCD, super 
LCD [11]. Moreover, we already presented various research 
reports concerning LCD, M value, ketone bodies and related 
investigation [12-14]. 
In this study, we combined two research methods together. One 
is the research axis from HOMA including HOMA-R and HOMA-β, 
and another is the axis of daily profile of glucose, average blood 
glucose a day and Morbus (M) value. M value has been one of 
the import biomarkers, which indicates average blood glucose 
level and mean amplitude of glycemic excursions (MAGE). In 
clinical research M value has been useful for its numerical value, 
because the degree of glucose variability can be indicated and 
compared in various situations. 
Subjects and Methods
Subjects in this study were 52 patients with type 2 diabetes 
mellitus (T2DM). For further evaluation and treatment of 
T2DM, they were admitted to the hospital. The subjects were 
admitted to the hospital for 14 days. They were not given any 
medications that may have altered the glucose metabolism. 
There was a necessary condition when we enrolled the subjects. 
The level of immunoreactive insulin (IRI) should be 5 μU/mL 
and less than 5 IU/ml in the morning after overnight fast. The 
subjects with more than 5 μU/mL of IRI were excluded.
As to the methods, there have been standard protocols of 
evaluation and treatment for T2DM in our clinical study. It 
includes nutritional therapy of standard meal with CR in day 1 
and 2, and LCD in after day 3. According to current study, the 
procedures were described in the following:
a) On the morning of day 2 after overnight fast, blood samples 
were drawn for basal blood tests. They included complete 
blood count, liver and renal function, lipids, HbA1c, glucose, 
IRI, C-peptide and so on. From these data, HOMA-R and 
HOMA-β and other biomarkers were calculated.
b) In our protocol, subjects are to take CR on day 1 and 2, with 
1400 kcal/day. The content of CR has 15% of protein, 25% of 
fat and 60% of carbohydrate. It is along the standard ratio of 
the macronutrients due to Japan Diabetes Association [15]. 
c) Regarding to daily profile of blood glucose in the subjects, 
blood samples were taken seven times a day on Day 2. 
d) This report has concentrated in the investigation of 1) 
fundamental data related to diabetes such as HbA1c, glucose, 
insulin, C-peptide, lipid and so on, 2) daily profile of blood 
glucose in day 2, with the calculation of M value, 3) HOMA-R 
and HOMA-β with the calculation of glucose and IRI on Day 2. 
This study is focused these aspects, and is not studied after 
clinical situation after Day 3.
Daily Profile of Blood Glucose 
As to glucose variability in a day, we checked the daily profile 
of blood glucose on day 2 for 7 times a day. The clock time was 
0800, 1000, 1200, 1400, 1700, 1900, 2200h. According to these 
data, the results of average blood glucose and M value were 
obtained [16,17].
Morbus Value 
One of the biomarker indicating the glucose variability is Morbus 
(M) value. It means the average blood glucose level and also the 
mean amplitude of glycemic excursions (MAGE) [16-18]. In clinical 
studies, M value has been useful, because it shows numerical 
values that can be compared and evaluated in various diabetic 
situations with glucose variability. Thus, M value indicates the 
degree of high blood glucose and the degree of swinging blood 
glucose. In the light of mathematics, M value is obtained by the 
logarithmic transformation. Its clinical significance would be the 
glucose deviation from the ideal glucose variability [17-19].
The formula of M value is described as follows: 
Firstly, M = MBS + MW : M value means the total of MBS and 
MW. Secondly, MW means maximum blood glucose − minimum 
glucose)/20. Lastly, MBS is the mean of MBSBS. When summarized 
the content above, MBSBS has been the individual M-value for 
each blood glucose, calculated as (absolute value of [10 × log 
(blood glucose level/120)])3 [17-19]. In the formula of M value, 
there is one part of 10xlog plasma glucose / 120. It means that 
when the blood glucose value is 120 mg/dL, the level of M value 
becomes minimum. Moreover, there is a part to calculate by 
the cube of the absolute value. Therefore, as the average blood 
glucose increases, the degree of increase in M value increases 
to large extent.
Generally, the obtained data of the M value is clinically judged 
as follows: less than 180 is normal range, from 180 to 320 is 
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borderline, more than 320 is abnormal.
By the level of M value, 52 subjects were divided into 4 groups 
with 13 cases each. M values shows both of mean blood glucose 
and mean amplitude of glycemic excursions (MAGE), then the 
purpose of the classification was to compare the variability of 4 
groups in several biomarkers.
Statistical Analysis
Regarding this study, data were shown by mean and standard 
deviation. In addition, data was described as the median 
and quartile of 25% / 75% according to the necessity of the 
biomarkers. Boxplot was used for the comparison among some 
groups, which expresses the median and the quartile of 25% 
/ 75%, maximum and minimum. As to investigation for the 
correlation with biomarkers, we used Spearman test to obtain 
the correlation coefficients. We used the standard statistical tool 
for analytical evaluation [20].
Ethical Standards
Current research was conducted in compliance with the ethical 
principles which were based upon the Declaration of Helsinki. 
Moreover, additional commentary was performed in 2004 
General Assembly Tokyo, Japan. It was conducted with Personal 
Information Protection Law and in reference to “Standards for 
the Implementation of Clinical Trials (GCP), an ordinance of the 
Ministry of Health, Labor and Welfare No. 28 of March 27, 1997. 
In addition, there was the “Ethical Guidelines for Epidemiology 
Research” by the Ministry of Education, Culture, Sports, Science 
and Technology and the Ministry of Health, Labor and Welfare.
Authors and colleagues had an ethical committee including 
physician, nurse, pharmacist and other experts in the legal 
specialty. We have discussed and confirmed that current study 
is valid and agreed with all members. Furthermore, informed 
consents and written paper agreements have been taken 
from the subjects. This study has been registered by National 
University Hospital Council of Japan (ID: #R000031211).
Results
1) Fundamental data
Basal data of 52 subjects were shown in (Table-1). Average age 
was 62.3 years old, and the HbA1c and average blood glucose was 
8.0% and 222 mg/dL, respectively. The median value of Morbus 
value, HOMA-R, HOMA-β was 151, 1.07, 11.1, respectively. Lipid 
profile and renal function tests revealed within normal range. 
Mean ± SD median [25%-75%]
Subjects
   numbers (M/F)
   age(years old)
52 (33/19)
62.3 ± 10.2
52 (33/19)
65 [58-69]
Glucose profile
   HbA1c (%)
   average glucose (mg/dL)
    Morbus value    
8.0 ± 1.8
222 ±85
271 ± 310
8.0 [6.4-9.2]
210 [148-281]
151 [40-412]
Insulin resistance
   HOMA - R
   HOMA - β
1.21 ± 0.60
131± 8.6
1.07 [0.77-1.61]
11.1 [7.3-9.3]
Lipid profile
   Triglyceride (mg/dL)
   HDL-C (mg/dL)
   LDL-C (mg/dL)
113 ± 92.7
71.9 ± 20.8
134 ± 38.3
79 [60.3-142]
66.5 [57.5-82.0]
136 [110-158]
Renal function
   Creatinine(mg/dL)
   Ccr (ml/min)
   Uric Acid (mg/dL)
0.72 ± 0.15
95.9 ± 24.3
5.0 ± 1.2
0.73 [0.62- 0.79]
94.0 [79.7-109]
4.9 [4.3-5.9]
Table 1 : Subjects and basal data
Morbus value was calculated from daily profile of glucose.
HOMA - R : Homeostatic model assessment of insulin resistance 
HOMA - β : Homeostasis model assessment for β cell function
2) Categorization by M value 
Subjects were divided into 4 groups due to the level of M value. 
Each group has 13 cases. The median of M value in group 1,2,3,4 
was 14.9, 77.3, 222, 701, respectively (Figure-1). From group 1 
to group 4, the level of M value has increased remarkably.
3) Comparison of biomarkers
As to average blood glucose, group 1 to 4 revealed 132 mg/dL, 
175 mg/dL, 232 mg/dL, 333 mg/dL in median value, respectively 
(Figure-2a). In four groups, median HbA1c value revealed 6.1%, 
7.0%, 8.1%, 9.8%, respectively (Figure-2b).
Similarly, median value of HOMA-R revealed 0.68, 1.08, 1.64, 
1.38, respectively (Figure-3a). The distributions of group 3 and 
group4 were rather overlapped. In addition, median value of 
HOMA-β revealed 16.9, 16.3, 10.2, 5.3, respectively (Figure-3b). 
The distribution of group 1 and 2 showed rather wide, while that 
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of group 3 and 4 showed less. 
4) Correlation between M value and HOMA
Correlation between Morbus value and HOMA was investigated 
(Figure-4). There was significant correlation (p<0.05) between 
M value and HOMA-R (Figure-4a). There was also significant 
correlation (p<0.01) between M value and HOMA-β (Figure-
4b). The significant degree was larger in HOMA-β than HOMA-R.
Figure 1: Categorization to 4 groups due to Morbus value
Figure 2a: The level of average blood glucose 
increased from group 1 to group 4.
Figure 3a: The value of HOMA-R seems to be higher 
in group 3 and 4 compared with group 1 and 2.
Subjects were categorized into 4 groups due to the level of M value.
The level of M value ranges wide, which is one of the characteristic point.
Figure 2: Average Glucose and HbA1c in four groups 
Figure 3: HOMA-R and HOMA-β in four groups
Figure 2b: The median HbA1c increased from 
group1 and 4.        
Figure 3b:The value of HOMA-β decreased from 
group 1 to group 4.
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Discussion
Regarding the effects on blood glucose, carbohydrates, lipids, 
and proteins were previously thought to be involved. Howev-
er, nutritional therapy for diabetes has changed since the an-
nouncement of ADA in 2004 [21]. Among three macronutri-
ents, it is only glucose that directly affects blood sugar after 
ingestion. 
In succession, clinical risk of hypoglycemia due to intensive 
therapy for diabetes has been known by the results of ACCORD 
study and others [22,23]. Consequently, LCD has been rather 
developed in many countries and its beneficial aspects were 
reported [6,7,24]. According to the result of PURE study, high 
carbohydrate intake was associated with higher risk of total 
mortality, whereas total fat and individual types of fat were re-
lated to lower total mortality [25]. 
The authors have continued clinical practice and research for 
many patients with diabetes. Among them, the authors have 
firstly reported on LCD study in Japan, and developed investiga-
tion utilizing both CR and LCD as a diet therapy. There are three 
directions in the following.
Firstly, we reported the effect of LCD on many cases, and also 
developed three kinds of LCD, which are super-, standard- and 
petite-LCD meal [11]. Among them, there are investigations of 
elevated ketone bodies in subjects on LCD meal and in the axes 
of fetus, placenta, newborn and pregnant women [12]. 
Secondly, our research has focused on the comparison with CR 
and LCD. One of the protocols includes that subjects are provid-
ed CR on days 1 and 2, LCD on 3-14 days for diabetic patients. 
Thus, all related biomarkers have been investigated such as dai-
ly profile of blood glucose, mean blood glucose level, M value, 
insulin, blood and urine value of C peptide, lipid, renal function 
and so on [13].
Thirdly, 70 g of carbohydrate in standard CR breakfast has been 
used for research, which is similar to 75g OGTT. It can show 
enough responses of glucose, insulin and c-peptide, where 
there is clinically significant for simple and usual loading of car-
bohydrate [31]. Consequently, CR breakfast with carbohydrate 
70g can be used and recommended for clinical research be-
cause of its practical convenient efficacy.
Based on our research background as mentioned above, we 
have conducted current research. Concerning the results in this 
study, the levels of M value in 4 groups showed large difference. 
It has been useful biomarker because its numerical values indi-
cate both of mean blood glucose and mean amplitude of gly-
cemic excursions (MAGE) [16-19]. In addition, average glucose 
was calculated from blood sampling 7 times a day. There were 
previous clinical data concerning the result of comparison be-
tween sampling of 7 times and 20 times. Both showed similar 
results about average blood glucose. Consequently, both would 
have compatible data, as well as the results from continuous 
glucose monitoring (CGM) [27-29].
Regarding the average glucose and HbA1c in 4 groups, their dis-
tribution seemed to be rather divided in the former, and rath-
er overlapped in the latter. The median values of HbA1c in 4 
groups were increased from group 1 to 4.  
As to HOMA-R, the median value was not so divided in 4 groups; 
especially the values in group 3 and 4 were overlapped, sug-
gesting increased insulin resistance. In the case of HOMA-β, the 
distributions of group 1 and 2 were almost overlapped, while 
the value of group 3 and 4 were remarkably low. The median 
value of HOMA-β decreased clearly from group 1 to 4, suggest-
ing the decreased ability of β cell function and low secretion 
of insulin.
There are significant correlation between M value and HO-
MA-R, and between M value and HOMA-β. The correlation co-
efficient is higher in HOMA-β than HOMA-R, suggesting higher 
relationship of secretion of insulin and clinical significance of 
M value.
In clinical studies, HOMA has been known as the useful bio-
marker for diabetes. In the case of calculation for HOMA, fast-
ing blood glucose and fasting insulin value are utilized. Origi-
nally, HOMA was developed by Matthews [5]. By mathematical 
assessment, HOMA is calculated from the balance between 
hepatic glucose output and insulin secretion from fasting levels 
of glucose and insulin [30]. Regarding clinical significance and 
Figure 4:Correlation between Morbus value and HOMA
Figure 4a: There was significant correlation between Morbus 
value and HOMA-R (p<0.01).
Figure 4b:There was significant correlation between Morbus 
value and HOMA-β (p<0.01).
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implications of HOMA, we can infer the functions of both ability 
to secrete insulin and resistance of insulin. There have been 
used two formula of HOMA, which are HOMA-R and HOMA-β.
As the value of HOMA-R becomes higher, the insulin resistance 
shows higher. Regarding the standard value of HOMA-R, it has 
been 1.73 or more with the presence of insulin resistance [31]. 
In addition, people with higher HOMA-R tend to suffer from 
myocardial infarction and cerebral infarction, regardless of di-
abetes. In other words, HOMA-R is not only for the judgment 
of insulin resistance but also for an indicator of cerebral cardio-
vascular events.
Regarding HOMA-β, the standard value for people in western 
countries would be 100%. On the other hand, it is known that 
Japanese people have less ability to secrete insulin. Therefore, 
the standard value for Japanese people has been set at 70% 
[32]. From previous studies, the following tendency has been 
known. 
Higher HOMA-R and lower HOMA-β were independently and 
consistently associated with an increased diabetes risk [31]. 
Compared the obtained data of HOMA-R and HOMA-β, most 
subjects in this study did not show normal ranges, suggesting 
the existence of insulin resistance and decreased β-function. 
For the limits of the research, several matters would be consid-
ered. This report has focused in the investigation of the follow-
ing 3 aspects, which are fundamental data related to diabetes, 
daily profile of blood glucose and M value in day 2, HOMA-R 
and HOMA-β on Day 2. Data obtained from Day 2 were utilized. 
Other factors would be explored in the light of the correlation 
with biomarkers related to diabetes. For example, urinary ex-
cretion of C-peptide, the response of glucose and IRI against 
70g of carbohydrate as breakfast, basal data of renal and liver 
function tests and so on. As to fasting IRI level, subjects with 
5 μU/mL and less than 5 μU/mL were included in this study. 
The reason was to reduce the larger error in calculating HOMA 
values. Consequently, subjects with more than 5 μU/mL of IRI 
would be investigated in the future study.
Conclusion
In summary, we investigated 52 patients with T2DM. Several re-
lated biomarkers such as HbA1c, the daily profile of glucose, av-
erage glucose, M value, HOMA-R, HOMA-β were measured and 
correlations were studied. Current results suggest that patients 
have insulin resistance and decreased β cell function correlated 
to the severity of diabetes. These findings would become the 
basal data in this field, and further development would be nec-
essary in the future research.
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